February 15, 2026 a 08:38 pm
BDX: Analysts Ratings - Becton, Dickinson and Company
The stock of Becton, Dickinson and Company (BDX) has experienced a mixed trend in recent analyst recommendations, with a notable stability in "Hold" ratings. The company's consistent focus on innovation and broad product portfolio supports its positive sentiment, but ongoing market dynamics in the healthcare industry may introduce variability. This analysis explores the latest trends and sentiment shifts around BDX.
Historical Stock Grades
Detailed assessment of recent analyst ratings reveals a consistent inclination towards maintaining existing recommendations with signs of a slight shift towards caution. Below is a summary of the latest ratings.
| Rating | Count | Score |
|---|---|---|
| Strong Buy | 2 | |
| Buy | 4 | |
| Hold | 9 | |
| Sell | 0 | |
| Strong Sell | 0 |
Sentiment Development
The sentiment for BDX has experienced notable shifts, especially with a rise in "Hold" ratings over recent months.
- Overall ratings from analysts have slightly decreased, indicating a possible increase in caution or uncertainty.
- Hold recommendations have steadily increased, showcasing a more cautious or neutral stance prevailing among analysts.
- The number of Strong Buy recommendations has consistently declined from 6 to 2 over the last year.
Percentage Trends
Over recent months, the percentage of "Buy" recommendations has been relatively stable with a declining trend in "Strong Buy" recommendations.
- In recent months, "Hold" has dominated the percentage share, indicating more reservations among analysts.
- The proportion of "Strong Buy" ratings fell significantly, reflecting a conservative shift.
- The last quarter of the analyzed period shows a stabilization of sentiments, with Hold recommendations comprising the largest share.
Latest Analyst Recommendations
Recent updates show maintenance in most recommendations, reflecting a steady market perspective. Here are the latest analyst positions:
| Date | New Recommendation | Last Recommendation | Publisher |
|---|---|---|---|
| 2026-02-11 | Buy | Buy | Citigroup |
| 2026-02-10 | Neutral | Neutral | Piper Sandler |
| 2026-02-10 | Equal Weight | Equal Weight | Wells Fargo |
| 2026-02-10 | Buy | Buy | Citigroup |
| 2026-02-10 | Sector Perform | Sector Perform | RBC Capital |
Analyst Recommendations with Change of Opinion
Changes in opinions reflect a strategic readjustment by some analysts. Below are notable changes:
| Date | New Recommendation | Last Recommendation | Publisher |
|---|---|---|---|
| 2025-05-22 | Neutral | Buy | Citigroup |
| 2025-05-02 | Neutral | Overweight | Piper Sandler |
| 2025-05-01 | Market Perform | Outperform | William Blair |
| 2024-10-01 | Buy | Neutral | Citigroup |
| 2023-07-24 | Outperform | Market Perform | Raymond James |
Interpretation
Overall, the analyst sentiment towards Becton, Dickinson and Company appears relatively stable with a cautious edge. The shift from "Strong Buy" to more neutral stances implies a careful market assessment. This could indicate an awareness of industry challenges or anticipation of market changes. The consistent level of "Hold" ratings reflects a stable, yet cautiously optimistic view on BDX's performance.
Conclusion
In summary, Becton, Dickinson and Company's stock shows signs of cautious stability among analysts, aligned with current marketplace conditions. Despite a reduction in aggressive buying strategies, the company's core strengths in innovation and healthcare solutions provide potential for future growth. Analysts' ratings suggest a balanced view, weighing opportunities against inherent market risks, making BDX a steady investment in a volatile industry.